Steminent Biotherapeutics Inc. (“Steminent”) is a leading stem cell research and development company with offices in Taipei, Shanghai and San Diego which is dedicated to the development of novel cellular therapeutics for the treatment of diseases with unmet or under-served medical needs.
Steminent utilizes advanced, proprietary processes and know how to isolate, purify, and amplify standardized stem cell products of the highest quality for research and clinical development in multiple indications.
Our Value Propositions
Steminent is a cell therapy research, manufacturing and development company which seeks to translate our technology platform into numerous cellular therapeutic candidates for clinical development and to optimize the commercialization potential of these cell therapy product candidates through global partnering initiatives to build substantial value for our shareholders.
Steminent’s portfolio of Stemchymal® cell therapy R&D programs have been generated from a validated platform of allogeneic stem cells, initially targeting neurodegenerative and other degenerative diseases. Steminent has built a pipeline of pre-clinical and clinical stage therapeutic programs for the treatment of a range of diseases including: Phase 2; spinocerebellar ataxia (PolyQ SCA), Phase I; osteoarthritis of the knee, and PC; other neurodegenerative diseases, and acute diseases (i.e. Acute Liver Failure and Post-CPR Syndrome).
A private company founded in 2009, Steminent has leveraged their solid pre-clinical data, early PI/II clinical data, and thorough CMC approach, to advance selected Stemchymal® cellular therapeutic programs with support and direction from numerous scientific, clinical and regulatory advisors and collaborators in Taiwan, Asia, US and EU.